Latest Posts

Amendment to PMPRB Compendium of Policies, Guidelines and Procedures Takes Effect

On September 1, 2016, the Patented Medicine Prices Review Board (the “PMPRB” or the “Board”), Canada’s independent quasi-judicial patented drug price watchdog, implemented an amendment (the “Amendment”) to section C.11 “Review of Prices of New Patented Drug Products at Introduction” of the Compendium of Policies, Guidelines and Procedures (the “Guidelines”)1. The Amendment brings an incremental but important change to the Guidelines, of which patentees in the pharmaceutical, biotechnology, and healthcare industries should be aware.

Read Full Article
Regulating Risk: Keeping You Up-To-Date on Product Regulation - September 2016

Here’s a look at what’s new with product regulation and oversight in Canada.

Read Full Article
The Ongoing Evolution of Canada’s Regulation of Marijuana

In the ongoing evolution of Canada’s marijuana laws, this summer, Health Canada implemented the new Access to Cannabis for Medical Purposes Regulations (“ACMPR”).  The ACMPR came into force on August 24, 2016 (replacing the old Marihuana for Medical Purposes Regulations) and provide increased access for Canadians who have been authorized by their healthcare practitioners to use cannabis for medical purposes.

Read Full Article
An Opportunity to Reshape Patented Medicines Regulation in Canada

The Patented Medicine Prices Review Board (the “PMPRB” or the “Board”) is currently canvassing stakeholder input on its Discussion Paper1 released on June 24, 2016, as part of an initiative to reform and modernize its regulatory framework.  

Read Full Article
Regulating Risk: Keeping You Up-To-Date on Product Regulation - May 2016

Here’s a look at what’s new with the Canada Consumer Product Safety Act and regulations to the Food and Drugs Act and Controlled Drugs and Substances Act.

Read Full Article
Prev 1 2 3